【摘要】 目的探讨利培酮与氟哌啶醇治疗儿童抽动障碍的临床疗效。方法将78例儿童抽动障碍患儿随机分为利培酮组和氟哌啶醇组各39例,分别予以利培酮和氟哌啶醇治疗8周。采用临床整体印象量表(CGI)、治疗中需处理的不良反应症状量表(TESS)于治疗前、治疗第2周、第4周和第8周末对两组患儿进行评定,并记录用药量。结果治疗8周后,利培酮组和氟哌啶醇组的最高平均治疗剂量分别为(1.4±0.34)mg和(7.3±0.52)mg,治疗总体有效率分别为82%和82.3%,无显著性差异(P>0.05);不良反应的发生率分别为28.2%和76.9%,有非常显著性差异(P<0.01),其中以第2周为明显,两组均未见严重不良反应。结论利培酮和氟哌啶醇对儿童抽动障碍患儿均具有较好疗效,但利培酮的安全性和依从性更高。更多还原

【Abstract】 ObjectiveTo explore the efficacy and safety of risperidone and haloperidol in treating Tic disorder.Methods78 patients with Tic disorder were randomly divided into the risperidone group and haloperidol group with 39 cases in each group and treated with risperidone and haloperidol respectively for 8 weeks. All patients of two groups were assessed with the Clinical Global Impression Scale (CGI) and Treatment Emergent Symptom Scale (TESS) before treatment and at the end of the 2nd, 4th and 8th week after treatment. Dosages of patients of two groups were recorded.ResultsAfter 8 weeks treatment, the average maximum dosage of risperidone was (1.4±0.34)mg, and that of haloperidol was (7.3±0.52)mg. The total effective rate of risperidone group was 82% and that of haloperidol group was 82.3 %. There was no significant difference between two groups ( P>0.05). The incidence of adverse reactions in risperidone group was 28.2%, and that in haloperidol group was 76.9%. There was a significant difference between two groups ( P<0.01), especially at the end of 2nd week after treatment.ConclusionRisperidone and haloperidol both are effect on Tic disorder, but safety and compliableness of risperidone are higher.更多还原